Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 28c
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
UBAB, LOAN, FITB, More
Revenue Growth %: +6.2%
Financial Fact:
Research and development: 2.49M
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.53, $0.28 better than the analyst estimate of $0.25. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $92.73 million.
GUIDANCE:
Catalyst Pharmaceuticals sees Q3 2023 revenue of $380-390 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- Washington Federal (WAFD) Misses Q3 EPS by 1c
- Regions Financial (RF) Tops Q2 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
